Valuation: Provectus Biopharmaceuticals, Inc.

Market Cap 25.17M 22.09M 20.57M 18.92M 35.47M 2.41B 36.08M 244M 95.54M 1.19B 94.51M 92.47M 4.12B P/E 2024
-10.6x
P/E 2025 -4.33x
Enterprise Value 27.9M 24.49M 22.8M 20.97M 39.32M 2.67B 39.99M 271M 106M 1.32B 105M 102M 4.57B EV / Sales 2024
86,451,912x
EV / Sales 2025 78,013,766x
Free-Float
92.52%
Yield 2024 *
-
Yield 2025 -
07-07 Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose CI
06-25 Provectus Biopharmaceuticals, Inc. Launches Veripure Open Science Program For Medical Research Access To PV-10 CI
06-19 Provectus Biopharmaceuticals, Inc. - Shareholder/Analyst Call
05-18 Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study RE
05-18 Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study CI
05-14 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-04 Provectus Biopharmaceuticals, Inc. Presents New Data on Rose Bengal Photodynamic Antimicrobial Therapy At Arvo 2026 CI
04-02 Provectus Biopharmaceuticals Highlights Preclinical Evidence Of PV-10-Mediated Immune Modulation In Burn Wound Healing CI
03-26 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-26 Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
11-13 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
09/10/25 Provectus Biopharmaceuticals Positions Pv-10 as Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel Sting-Pathway Activation for Improving Hepatitis B Vaccine Efficacy CI
29/09/25 Provectus Biopharmaceuticals initiates preclinical study of oral PV-10 RE

Last Transcript: Provectus Biopharmaceuticals, Inc.

1 day-0.17%
1 week+0.67%
Current month-13.69%
1 month-10.06%
3 months+17.45%
6 months+9.91%
Current year+7.16%
1 week 0.06
Extreme 0.055
0.07
1 month 0.06
Extreme 0.055
0.08
Current year 0.04
Extreme 0.038
0.08
1 year 0.04
Extreme 0.038
0.1
3 years 0.04
Extreme 0.038
0.22
5 years 0.03
Extreme 0.034
0.22
10 years 0.01
Extreme 0.011
0.31
Manager TitleAgeSince
Chief Executive Officer 73 16/04/2024
Chief Tech/Sci/R&D Officer 62 15/05/2012
Director of Finance/CFO 59 25/03/2019
Director TitleAgeSince
Chairman 57 03/04/2017
Director/Board Member 78 27/04/2018
Chairman 73 27/04/2018
Date Insider Type Main position Quantity % Market Cap.
6/30/26 A Free

Chairperson

45,860 0.4858%
6/30/26 A Free

Director

48,917 0.5182%
6/30/26 A Free

Director

48,917 0.5182%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%+0.67%-24.27%-45.55% 25.17M
-0.80%+1.11%+49.07%+67.79% 55.01B
-1.32%-2.71%+34.27%+77.57% 54.24B
+1.49%+0.13%-18.03%-13.94% 23.38B
-0.57%-4.13%+2.34%+387.73% 22.57B
+2.23%+1.96%+17.86%-10.20% 20.19B
-0.21%-0.65%+29.41%-31.88% 17.86B
-2.18%-3.79%+26.18%+558.37% 15.5B
-6.69%-5.11%+169.13%+304.89% 14.2B
+1.25%+0.69%+27.30%+184.69% 14.2B
Average -0.68%-0.54%+31.33%+147.95% 23.72B
Weighted average by Cap. -0.65%-0.52%+34.87%+131.52%

Financials

2024 2025
Net sales 0.62 0.54 0.5 0.46 0.87 58.96 0.88 5.98 2.34 29.24 2.32 2.27 101.02 0.34 0.29 0.27 0.25 0.47 32.11 0.48 3.26 1.28 15.92 1.26 1.23 55.02
Net income -4.76M -4.18M -3.89M -3.58M -6.71M -455M -6.83M -46.17M -18.07M -226M -17.88M -17.49M -780M -5.43M -4.77M -4.44M -4.08M -7.65M -519M -7.78M -52.65M -20.61M -257M -20.39M -19.95M -889M
Net Debt 2.88M 2.53M 2.35M 2.16M 4.05M 275M 4.12M 27.9M 10.92M 136M 10.8M 10.57M 471M 2.73M 2.39M 2.23M 2.05M 3.84M 261M 3.91M 26.44M 10.35M 129M 10.24M 10.02M 446M
Logo Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
Employees
6
Date Price Change Volume
28/07/26 $0.0599 -0.17% 78,269
27/07/26 $0.0600 -3.40% 121,200
24/07/26 $0.0621 -0.45% 124,117
23/07/26 $0.0624 +7.79% 568,572
22/07/26 $0.0579 -2.72% 349,550
  1. Stock Market
  2. Stocks
  3. PVCT Stock